Back to search results
NCT00209235

Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

Active, Not Recruiting
NAAges 2ā€“89Interventional
Connecticut Children's Medical Center
~600 participants
Updated 2026-06-02 on ClinicalTrials.gov
What's tested:Neurocognitive and psychosocial testing

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PHP1A: Effect of GH on height, growth velocity, final height in children. Effect on weight, BMI, lipids, BMD, self-esteem in all ages.
Measured over until achieve final height (approximately 12-15 years)
+1 more outcome measured

Conditions

Pseudohypoparathyroidism Type 1A
Albright Hereditary Osteodystrophy
Pseudopseudohypoparathyroidism

Explore related trials

Albright Hereditary Osteodystrophy without Multiple Hormone ResistanceAlbright's Hereditary OsteodystrophyGrowth Hormone DeficiencyGNAS Gene

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Emily L Germain-Lee, MD Ā· PRINCIPAL_INVESTIGATOR Ā· Connecticut Children's Medical Ctr. and Univ. of Connecticut School of Medicine

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation ā€” and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min Ā· HIPAA-protected Ā· delete anytime
Eligibility criteria

Inclusion

Diagnosis of pseudohypoparathyroidism type 1A with mutation confirmation and already enrolled previously.
For the portion of the study in which growth hormone was/is used for participants who are not growth hormone deficient (ie., growth hormone sufficient), the participant had to be over 3 years of age (ie., after 3rd birthday) AND also had to be pre-pubertal at the time of GH initiation; they must have been previously enrolled.
The growth hormone sufficient participants met the FDA-approved criteria for idiopathic short stature or the SGA indication and were previously enrolled.
Absence of above diagnosis and failure to meet above criteria
Confirmed diagnosis of Pseudohypoparathyroidism type 1A and Pseudopseudohypoparathyroidism with mutation confirmation and already enrolled previously.
Ages 4 - 65 yrs
Absence of above
Confirmed diagnosis of Pseudohypoparathyroidism type 1A or Pseudopseudohypoparathyroidism with mutation confirmation and also enrolled previously.
Ages 0.2 yrs - 89 yrs
Absence of above

What this trial measures

  • PHP1A: Effect of GH on height, growth velocity, final height in children. Effect on weight, BMI, lipids, BMD, self-esteem in all ages.until achieve final height (approximately 12-15 years)

    Effect of growth hormone

  • Cognitive and behavioral function in Albright hereditary osteodystrophyparticipant will be assessed on day 1; assessment may extend into day 2

    Cognitive and behavioral function assessments/questionnaires